NAS:BVXV (Israel)  
BiondVax Pharmaceuticals Ltd logo

BiondVax Pharmaceuticals Ltd

$ 0.72 -0.0147 (-2.01%) 10:10 AM EST
P/E:
N/A
P/B:
29.72
Market Cap:
$ 14.07M
Enterprise V:
$ 23.67M
Volume:
10.23K
Avg Vol (2M):
82.06K
Also Trade In:
Volume:
10.23K
Market Cap $:
14.07M
PE Ratio:
N/A
Avg Vol (2-Month):
82.06K
Enterprise Value $:
23.67M
PB Ratio:
29.72
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.
Name Current Vs Industry Vs History
Cash-To-Debt 0.51
Equity-to-Asset 0.05
Debt-to-Equity 17.25
Debt-to-EBITDA -2.7
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 28.8
3-Year FCF Growth Rate 32.6
Name Current Vs Industry Vs History
5-Day RSI 28.52
9-Day RSI 28
14-Day RSI 28.4
6-1 Month Momentum % -33.43
12-1 Month Momentum % -49.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.71
Quick Ratio 1.71
Cash Ratio 1.68

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROE % -353.25
ROA % -46.76
ROIC % -50.3
ROC (Joel Greenblatt) % -68.44
ROCE % -56.4

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio N/A
N/A
N/A
PE Ratio without NRI N/A
N/A
N/A
PB Ratio 29.72
Price-to-Tangible-Book 25.1
EV-to-EBIT -5.54
EV-to-EBITDA -5.91
EV-to-FCF -7.09
Earnings Yield (Greenblatt) % -18.05

Financials (Next Earnings Date:2023-01-28 Est.)

BVXV's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BVXV

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.896
Beta 2.63
Volatility % 81.13
14-Day RSI 28.4
14-Day ATR ($) 0.096699
20-Day SMA ($) 0.964185
12-1 Month Momentum % -49.77
52-Week Range ($) 0.646 - 3.49
Shares Outstanding (Mil) 18.68

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BiondVax Pharmaceuticals Ltd Filings

Document Form Filing Date
No Filing Data

BiondVax Pharmaceuticals Ltd Analysis

Share your research

Headlines

See More
No news.